fatty diacid comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
== Biological activity == Cortisol acts as an agonist of the corticosteroid receptors, including the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). Cortisol is also an agonist of membrane corticosteroid receptors, including membrane glucocorticoid receptors (mGRs) and membrane mineralocorticoid receptors (mMRs). In addition to its corticosteroid receptor agonism, cortisol has been reported to be a highly potent biphasic regulator of the GABAA receptor, acting as a positive allosteric modulator at low concentrations (1–10 pM) and as a negative allosteric modulator at high concentrations (10–1,000 nM).
=== Mechanism of action === Inhibition of serotonin and norepinephrine transporters by amitriptyline results in interference with neuronal reuptake of serotonin and norepinephrine. Since the reuptake process is important physiologically in terminating transmitting activity, this action may potentiate or prolong the activity of serotonergic and adrenergic neurons and is believed to underlie the antidepressant activity of amitriptyline. Inhibition of norepinephrine reuptake leads to an increased concentration of norepinephrine in the posterior gray column of the spinal cord appears to be mostly responsible for the analgesic action of amitriptyline. Increased level of norepinephrine increases the basal activity of alpha-2 adrenergic receptors, which mediate an analgesic effect by increasing gamma-aminobutyric acid transmission among spinal interneurons. The blocking effect of amitriptyline on sodium channels may also contribute to its efficacy in pain conditions. Amitriptyline also acts as NMDA receptor blocker, but the precise mechanism of this blockade remains unclear . Amitriptyline's blockade of various types ion channels may explain the high efficacy regarding Neuropathic pain.
Climate change in Brazil is causing higher temperatures and longer-lasting heatwaves, changing precipitation patterns, more intense wildfires and heightened fire risk. Brazil's hydropower, agriculture and urban water supplies will be affected. Brazil's rainforests, and the Amazon, are particularly at risk to climate change. At worst, large areas of the Amazon River basin could turn into savannah, with severe consequences for global climate and local livelihoods. Extreme weather events like droughts and flash floods are causing annual losses of around R$13 billion (US$2.6 billion), equivalent to 0.1% of the country's 2022 GDP. Climate impacts could exacerbate poverty. Brazil's greenhouse gas emissions per person are higher than the global average, and Brazil is among the top 10 highest emitting countries. Greenhouse gas emissions by Brazil are over 4% of the annual world total. In 2026 the Brazilian government has launched a National Climate Change Plan which should cut greenhouse gas emissions by 59% - 67% by 2035, and make the country carbon neutral by 2050. Brazil hosted the 2025 United Nations Climate Change Conference, in which it launched the Global carbon market coalition immediately joined by 11 countries including Brazil, China, the European Union, United Kingdom. According to some calculations, a global carbon market can speed up emission reduction seven-fold.
In addition, the Kanji of the Year (kotoshi no kanji) has been selected since 1995, and both the kanji and the word/phrase of the year often reflect current Japanese events and attitudes. For example, in 2011, following the Fukushima nuclear disaster, the frustratingly enigmatic phrase used by Japanese officials before the explosion regarding the possibility of a meltdown - "the possibility of recriticality is not zero" (Sairinkai no kanōsei zero de wa nai) - became the top phrase of the year. In the same year, the kanji for "bond" (i.e., family ties or friendship) became the kanji of the year, expressing the importance of collectiveness in the face of disaster. Liechtenstein: Word of the year (Liechtenstein) since 2002. In Norway, the Word of the year poll has been carried out since 2012. In Portugal, the Word of the year poll has been carried out since 2009. In Russia, the Word of the year poll has been carried out since 2007. In Slovenia, the word of the year poll has been carried out since 2016. Each year, it is announced in January together with the SSL (Slovenian Sign Language) gesture of the year. In Spain, a Word of the year has been selected by Fundéu since 2013. Switzerland: Word of the year (Switzerland), since 2003. In Ukraine, the Word of the year poll has been carried out since 2013. In The Netherlands, a word of the year poll is carried out by dictionary publisher Van Dale since 2007.
Sources: en.wikipedia.org
Inhaled medications can be absorbed quickly and act both locally and systemically. Proper technique with inhaler devices is necessary to achieve the correct dose. Some medications can have an unpleasant taste or irritate the mouth. In general, only 20–50% of the pulmonary-delivered dose rendered in powdery particles will be deposited in the lung upon mouth inhalation. The remainder of 50-70% undeposited aerosolized particles are cleared out of lung as soon as exhalation. An inhaled powdery particle that is >8 μm is structurally predisposed to depositing in the central and conducting airways (conducting zone) by inertial impaction. An inhaled powdery particle that is between 3 and 8 μm in diameter tend to largely deposit in the transitional zones of the lung by sedimentation. An inhaled powdery particle that is <3 μm in diameter is structurally predisposed to depositing primarily in the respiratory regions of the peripheral lung via diffusion. Particles that deposit in the upper and central airways are generally absorbed systemically to great extent because they are only partially removed by mucociliary clearance, which results in orally mediated absorption when the transported mucus is swallowed, and first pass metabolism or incomplete absorption through loss at the fecal route can sometimes reduce the bioavailability.
Proteomic profiling of mouse liver revealed that SIRT5 regulates about 16% of all identified malonyl-lysine sites, the majority of which contain only a single malonylated lysine residue. The proteins regulated in this way are mainly involved in glycolysis, gluconeogenesis, fatty acid oxidation, and the urea cycle. The moderate reduction in malonylation observed upon SIRT5 knockdown in turn suggests the presence of additional, unidentified demalonylases. It has also been proposed that demalonylases and deacetylases function less as dedicated regulatory enzymes and more as part of a protein quality-control mechanism.
Hydromorphone is a semi-synthetic μ-opioid agonist. As a hydrogenated ketone of morphine, it shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, and increased pinpoint constriction of the pupils.
=== Absorption === Bicalutamide is extensively and well-absorbed following oral administration, and its absorption is not affected by food. The absolute bioavailability of bicalutamide in humans is unknown due to its very low water solubility and hence lack of an assessable intravenous formulation. However, the absolute bioavailability of bicalutamide has been found to be high in animals at low doses (109% in mice at 10 mg/kg; 72% in rats at 1 mg/kg; 100% in dogs at 0.1 mg/kg), but diminishes with increasing doses such that the bioavailability of bicalutamide is low at high doses (10% in rats at 250 mg/kg; 31% in dogs at 100 mg/kg). In accordance, absorption of (R)-bicalutamide in humans is slow and extensive but saturable, with steady-state levels increasing linearly at a dosage of up to 150 mg/day and non-linearly at higher dosages. At higher dosages of 100 to 200 mg/day, absorption of bicalutamide is approximately linear, with a small but increasing departure from linearity above 150 mg/day. In terms of geometric mean steady-state concentrations of (R)-bicalutamide, the departures from linearity were 4%, 13%, 17%, and 32% with dosages of 100, 150, 200, and 300 mg/day, respectively. There is a plateau in steady-state levels of (R)-bicalutamide with bicalutamide dosages above 300 mg/day, and, accordingly, dosages of bicalutamide of 300 to 600 mg/day result in similar circulating concentrations of (R)-bicalutamide and similar degrees clinically of efficacy, tolerability, and toxicity.
== External links == Frontline: Dangerous prescriptions – Interview with Leo Lutwak, in which he discusses the side effects of fenfluramine (Pondimin), its successor dexfenfluramine (Redux), and the fen-phen combination. U.S. FDA fen-phen information Tellier P (November 2001). "Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts". Annales de Médecine Interne. 152 (7): 429–36. PMID 11965083.
Sources: en.wikipedia.org
The chemical nature of the stationary phase. The stationary phase can be coated with some ligands at different bonding densities (how many ligands are bonded per surface area). The composition of the mobile phase. The mobile phase may be made of one solvent, or a mixture of several solvents. The solvents can be mixed at different ratios. Different mobile phases have different properties, such as polarity. When a mobile phase consists of mostly one solvent, with some other solvents added in small amounts, those other solvents are called "mobile phase modifiers". The pH of the mobile phase, which affect the ionization state of the solutes and their polarity. This can be changed with additives such as buffers. Usually, the stationary phase is made of a layer of hydrophobic substrate bonded to the surface of porous silica gel particles. The particles come in various shapes (spheric, irregular), at different diameters (sub-2, 3, 5, 7, 10 μm), with varying pore diameters (60, 100, 150, 300 Å). The particle diameters are often given as mesh numbers. For example, 2500-mesh corresponds to a particle diameter of 5 μm. The hydrophobic substrates are generally alkyl chains, such as C3, C4, C8, C18, or more. The longer the chain, the longer the sample components will be retained. It would make the resolution power higher, but also make the chromatography take longer to run. Most current methods of separation of biomedical materials use C18 columns, sometimes called by trade names, such as ODS (octadecylsilane) or RP-18 (reverse phase 18).
Pancreatic elastase is a form of elastase that is produced in the acinar cells of the pancreas, initially produced as an inactive zymogen and later activated in the duodenum by trypsin. Elastases form a subfamily of serine proteases, characterized by a distinctive structure consisting of two beta barrel domains converging at the active site that hydrolyze amides and esters amongst many proteins in addition to elastin, a type of connective tissue that holds organs together. Pancreatic elastase 1 is a serine endopeptidase, a specific type of protease that has the amino acid serine at its active site. Although the recommended name is pancreatic elastase, it can also be referred to as elastase-1, pancreatopeptidase, PE, or serine elastase. The first isozyme, pancreatic elastase 1, was initially thought to be expressed in the pancreas. However it was later discovered that it was the only chymotrypsin-like elastase that was not expressed in the pancreas. In fact, pancreatic elastase is expressed in basal layers of epidermis (at protein level). Hence pancreatic elastase 1 has been renamed elastase 1 (ELA1) or chymotrypsin-like elastase family, member 1 (CELA1). For a period of time, it was thought that ELA1 / CELA1 was not transcribed into a protein. However it was later discovered that it was expressed in skin keratinocytes. Clinical literature that describes human elastase 1 activity in the pancreas or fecal material is actually referring to chymotrypsin-like elastase family, member 3B (CELA3B).
== Data analysis == Gel permeation chromatography (GPC) has become the most widely used technique for analyzing polymer samples in order to determine their molecular weights and weight distributions. Examples of GPC chromatograms of polystyrene samples with their molecular weights and dispersities are shown on the left.
== Other investments == In 2019, 777 Partners bought the London Lions, London's sole men's professional basketball team. They then invested £7 million for 45% of the British Basketball League (BBL). 777 sold a slight minority stake in the London Lions to O.G. Anunoby and became the first British team to ever qualify for EuroCup playoffs. In May 2024, British Basketball revoked the license of the operating company behind the BBL, due to concerns over its financing. The BBL folded and was replaced by Super League Basketball. In August 2024, administrators Hudson Weir allowed the London Lions to be sold to Tesonet, the creators of NordVPN and owners of Lithuanian team BC Žalgiris. The new owners defended their decision to keep Lenz Balan, former vice president of 777 Partners, as CEO of the Lions. In 2022, 777 invested in STX Entertainment, a global film studio known for producing films such as Molly's Game, The Irishman, and Ferrari.
In the 1950s and 1960s, most heroin was produced in Turkey and transshipped in France via the French Connection crime ring, with much of it arriving in the United States. This resulted in the record setting 26 April 1968 seizure of 246 lb (111.6 kg) of heroin smuggled in a vehicle on the SS France (1960) ocean liner. By the time of The French Connection (1971 film), this route was being supplanted. Then, until c. 2004, the majority of the world's heroin was produced in an area known as the Golden Triangle. However, by 2007, 93% of the opiates on the world market originated in Afghanistan. This amounted to an export value of about US$4 billion, with a quarter being earned by opium farmers and the rest going to district officials, insurgents, warlords and drug traffickers. Another significant area where poppy fields are grown for the manufacture of heroin is Mexico. In November 2023, a U.N report showed that in the entirety of Afghanistan, poppy cultivation dropped by over 95%, removing it from its place as being the world's largest opium producer. According to the United States Drug Enforcement Administration, the price of heroin is typically valued 8 to 10 times that of cocaine on American streets, making it a high-profit substance for smugglers and dealers. In Europe (except the transit countries Portugal and the Netherlands), for example, a purported gram of street heroin, usually consisting of 700–800 mg of a light to dark brown powder containing 5–10% heroin base, costs €30–70, making the effective value per gram of pure heroin €300–700.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.